L.J. Altfest & Co’s Nektar Therapeutics NKTR Stock Holding History

L.J. Altfest & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-399	Closed	-$201K	–	201
2019 Q1	$201K	Buy	+399	New	+$236K	0.05%	179

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

L.J. Altfest & Co's NKTR Position: Q2 2019 in Review

L.J. Altfest & Co sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 399 shares — an estimated $201K sold.

L.J. Altfest & Co first reported a position in NKTR in Q1 2019 and held it in 1 quarter. The position peaked at $201K in Q1 2019. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

L.J. Altfest & Co reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
L.J. Altfest & Co sold 399 Nektar Therapeutics shares in Q2 2019, an estimated $201K.
L.J. Altfest & Co first reported a position in Nektar Therapeutics in Q1 2019 and held it in 1 quarter.
L.J. Altfest & Co's Nektar Therapeutics position peaked at $201K in Q1 2019.
336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on L.J. Altfest & Co's 13F filing for Q2 2019, filed 15 Jul 2019.